RxDoctor Payments Data

Kenyatte Canidate

Psychiatric/Mental Health · Harrisburg, PANPI 1427562701

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,519 of the $8,290 with a category attached, or 78.6%. 12 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 42.1% of the total. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,290in general payments, 2019–2025

Across 372 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Neurocrine Biosciences, Inc.$951
  • AbbVie$907
  • Alkermes, Inc.$489
  • Axsome Therapeutics, Inc.$393
  • plus $1K from 6 others

What the payments were for

  • Speaking & faculty fees$1,60019%
  • Food & beverage$6,51979%
  • Education$1712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,290 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate21$60,754
CaplytaLumateperone Tosylate17$24,664
Paliperidone ErPaliperidone17$7,433
Chlorpromazine Hcl14$6,376
Oxcarbazepine34$2,180
Perphenazine18$1,968
Lurasidone Hcl14$1,954
Naltrexone Hcl20$1,945
Atomoxetine Hcl11$1,485
Haloperidol45$1,463
Olanzapine60$1,197
Quetiapine Fumarate20$1,149
Gabapentin39$1,141
Buspirone Hcl34$1,069
Trazodone Hcl78$1,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$179$60,75421 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,044$24,66417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →